anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This protocol represents a Phase II pilot prospective non-randomized single arm open-label study design. We aim to enroll 30 patients after heart transplantation (Study Group), who will meet all of the inclusion and none of the exclusion criteria and 60 propensity-matched historical controls (Controls; matched for gender, age, CMV serological status, CMV DNA quantification method, donor and transplant data and immunosuppresion treatment). All patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available). Patients in Controls will receive virostatic prophylaxis with valgancyclovir 450 mg bid. In all patients the virostatic prophylaxis will be initiated between days 4 and 7 after heart transplantation and the duration of virostatic prophylaxis will be determined by the Quantiferon-CMV assay. In all patients, initial Quantiferon-CMV assay evaluation will be performed 100 days post-heart transplant at which time PCR CMV assay will also be made. In patients with negative PCR CMV and Quantiferon-CMV values ≥ 0,2 IU/mL the virostatic therapy will be discontinued \[10\]. In patients with negative PCR CMV and Quantiferon-CMV values \< 0,2 IU/mL the virostatic prophylaxis will continue for additional 30 days at which point Quantiferon-CMV assay will be re-evaluated. In an event of CMV infection/disease CMV it will be treated using valgancyclovir (900 mg q12) or gancyclovir (5 mg/kg q12h) per discretion of the treating heart transplant cardiologist and resistance to virostatic therapy will be tested at this time point. All patients (Study Group and Controls) will receive immunosuppresion induction therapy and triple maintenance immunosuppression therapy (TAC/MMF/steroid), fungal (posaconazole - 6 months), and pneumocystis prophylaxis (TMP/SMX - lifelong). In the Study Group additional, HSV /VZV viral prophylaxis with valacyclovir (500 mg q12, adjusted for renal function) will be used for 6 months after heart transplantation. Patients will be followed on an outpatient basis monthly for 12 months after enrollment and the events will be recorded using the following definitions. The maximum expected duration of letermovir therapy in the Study Group will be equal to the duration of follow-up - 12 months. After completion of the study all patients in the Study Group that may still require CMV virostatic prophylaxis according to our institutional guidelines will be switched to the current standard of care at our institution - valgancyclovir.
The teachers of schools randomized to control arm will receive training in World Health Organization (WHO) School Mental Health Program (SMHP) by mental health experts at WHO collaborating center for mental health research and training, Institute of Psychiatry. The training of teachers will consist of a mix of both didactic and interactive training methodologies in the form of a workshop. The workshop will consist of lectures/presentations, incorporating group discussions/activities. Through didactic methods, teachers will be taught basic theoretical knowledge related to mental health in schools. Training will be followed by monthly supervision meeting of teachers for 9-months.
The present invention discloses the composition, extraction process and use of total triterpene sapogenin extracted from bamboo. The triterpene sapogenin is extracted from stem, branch, leaf, root, shoot, etc. of bamboo as one kind of gramineous plant via supercritical CO2 fluid extraction process. The test via vanillin-perchloric acid colorimetry method and GC-MS method shows that the extractive has total triterpene sapogenin content of 10-90 %, friedelin content of 5-35 % and lupenone content of 1-10 %. The extractive as one mixture of five-cycle triterpene compounds (EZR2002) has excellent physiological and pharmacological activity of resisting free radical, resisting oxidation, resisting tumor, lowering blood pressure, etc. and may be used in medicine and health care article for preventing and treating cardiac and cerebral vascular diseases and resisting tumor and may be also used in cosmetics.
Approximately 75 participants will be assigned to this study group. Participants will receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications AND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
AIMS: The purpose of this study was to evaluate the predictive value of inflammatory risk as defined by the Glasgow Prognostic Score (GPS) for cardiovascular death in patients with diabetes.
METHODS: This study included 4956 patients (≥18 years old) with diabetes in the National Health and Nutrition Survey from 1999 to 2010. The mortality rate was determined by the correlation with the national death index on December 31, 2019. The GPS was composed of the serum C-reactive protein and the albumin. The primary outcome was cardiovascular death and the secondary outcome was all-cause death. The Cox proportional risk model adjusted for demographic factors and traditional cardiovascular risk factors was used to analyze the cumulative risk of outcomes.
RESULTS: Among 4956 diabetes patients with a median follow-up of 10.9 years, 601 cardiovascular deaths and 2187 all-cause deaths were recorded. After adequate model adjustment, compared with the low GPS group, the high GPS group (HR, 1.257 (1.007-1.570), P = 0.043) had a higher cardiovascular mortality. Compared with the low GPS group, the all-cause mortality of the high GPS group (HR, 1.394 (1.245-1.560), P < 0.001) was higher. The results of subgroup analyses were similar with that of the overall cohort.
CONCLUSIONS: The inflammatory risk as defined by the GPS was closely related to the increased risk of cardiovascular and all-cause death in patients with diabetes. It may be a convenient and efficient clinical practical risk assessment tool for patients with diabetes.
FIELD: medicine, immunology. SUBSTANCE: immunological activity of definite bioactive substances is estimated by treatment of human peripheral blood leukocyte culture or murine resident peritoneal cells suspension (strain BALB/c) with substance to be tested in order to induce cytokine production. Cytokines were assayed by conventional methods of identification. Improved results can be obtained by addition of nonsteroid antiinflammatory drug, mainly indomethacin, to the tested solution. Method can be used for estimation of immunological response in human persons to therapy that uses substances inducing cytokine production. EFFECT: improved method of immunogenic activity estimation.
IMM-101 will be given in combination with standard treatment with ipilimumab. In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the ipilimumab cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
After coronary artery bypass graft surgery, patients will receive routine monitoring, pharmacological treatment and nursing care in the unit where the research is conducted. Cold gel pack will be placed around the patient's chest tube insertion area. In order to optimize the effect of cold, the cold application will not exceed 20 minutes and the temperature of the skin will not fall below 12 ℃. At the 10th minute of cold application, the vibration device will be placed proximal to the chest tube, over the upper area of the cold gel pack. At the 20th minute of the application, the patient's skin temperature will be measured and the cold applied vibration device will be pulled above the chest tube insertion area.
NEW MATERIAL:A compound shown by formula I {Y is group shown by formula II [B is phenyl (replaced with alkyl, carboxyl, etc.), heterocyclic-alkyl, etc.], -CidenticalC-D (D is alkyl or alkylcarbonyl), group shown by formula III (X is halogen), group shown by formula IV [E is alkyl (replaced with OH, etc.) or carboxyl- replaced phenyl], etc.; R1-R5 are H, OH, (OH-substituted)<=3 aliphatic hydrocarbon residue consisting of single or double bond, etc.} and a salt thereof. EXAMPLE:Caffeic acid p-n-butylanilide. USE:A drug such as remedy and preventive for allergic disease, asthma, inflammation, etc., having excellent inhibitory action on leukotriene and 5-lipoxygenase. PREPARATION:A compound shown by formula V or a reactive derivative thereof is reacted with a compound shown by formula VI in an inert organic solvent under anhydrous condition, in the presence of a condensation agent when the compound shown by formula V is a carboxylic acid, to give a compound shown by formula I wherein Y is group shown by formula II.
MTN-007 is a Phase 1, randomized, blinded, placebo-controlled safety and acceptability study of vaginally formulated tenofovir 1% gel (a reduced-glycerin formulation), when applied rectally. The primary objective of this study is to assess the safety of vaginally formulated tenofovir 1% gel when applied rectally. This study will also determine whether rectal use of tenofovir 1% gel is associated with rectal mucosal damage using a broad range of immunological safety biomarkers, utilizing N-9 as a positive control, as rectal application of N-9 is known to cause mild but transient mucosal damage. Other secondary objectives include evaluations of the acceptability of rectal administration of tenofovir 1% gel as well as the safety of hydroxyethylcellulose (HEC) placebo gel when applied rectally.

Participants will be randomized to receive a single dose of tenofovir 1% gel, 2% N-9 gel or a placebo gel that is applied by a clinician at the study site. The study will also include a no treatment arm. There will be 15 participants in each arm. Participants will return to the clinic, where they will self-administer a single dose of the study gel under observation. Within approximately 30 minutes, lavage, stool, and rectal biopsy specimens will be obtained. After a one-week recovery period, participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days. Participants will return to the clinic for evaluation and specimen collection after completion of 7 days of daily dosing.

Receptive anal intercourse is common among men who have sex with men and there is increasing evidence that heterosexual women in the developed and developing world also practice anal sex. It can therefore be anticipated that once vaginal microbicides are licensed, they will be used in both the vaginal and rectal compartments. As a consequence, there is a need to evaluate both the rectal and vaginal safety profile of candidate microbicides. The Rectal Microbicide Program clinical protocols have therefore been developed to assess the safety and pharmacology of tenofovir 1% gel when used rectally in men and women as well as address critical questions regarding rectal microbicides through exploratory objectives.
The screening phase is intended for diagnosing and assessing the patient for possible inclusion in the study and for providing an adequate washout period. The following study will be conducted in two parts. Part I is an open-label study, multiple center and dose escalation evaluation in twelve patients. Six subjects each will be evaluated for safety and efficacy assessments at 1 or 2 capsules TID dose for 28 days, sequentially. Each of them will be assessed twice in the first week after administration of PDC-1421 Capsules and once a week in the following treatment.

Part II is a randomized, double-blind, placebo-controlled, parallel-group study. 60 subjects will be randomly assigned on a 1:1:1 basis to one of the three arms (1 PDC-1421 Capsule plus 1 placebo TID, 2 PDC-1421 Capsules TID, 2 placebo TID) for 6 weeks and evaluated the safety and efficacy every two weeks during the treatment period.
The invention relates to retroviral expression vectors and more particularly to pseudotyped retroviral vectors for gene therapy of cancer. Direct in vivo tumor-targeting with 'suicide' viral vectors is limited by inefficient gene transfer and indiscriminate transfer of a contitionally toxic gene to surrounding non-malignant tissue. Retrovectors pseudotyped with a Vesicular Stomatitis Virus G protein (VSVG) may serve as a remedy to this conundrum. These retroviral particles differ from standard murine retroviruses by their very broad tropism and the capacity to be concentrated by ultracentrifugation without loss of activity. A VSVG-typed retrovector can be utilized for efficient and tumor specific Herpes Simplex Virus Thymidine Kinase (TK) gene delivery in vivo. A bicistronic retroviral vector which expresses TK and Green Fluorescence Protein (pTKiGFP) was constructed.
<P>PROBLEM TO BE SOLVED: To provide a desiccant which shows high safety when a person takes in the desiccant by accident, with regard to the desiccant usd for a medicine, foodstuff, etc. and also shows excellent moisture absorption characteristics.  <P>SOLUTION: The problem can be solved by adding an arginine acidic amino acid salt to the desiccant. That is, the applicable arginine acidic amino acid salt is of a such type that can be obtained in nature, or with the help of a microbe and from a processed product of the microbe or by a chemical synthesis, etc. Besides, the commercial grade product of the amino acid salt can be used. In addition, for the acidic amino acid salt, a glutamate is preferably used. Besides, the desiccant can be used by bringing it into contact directly with the medicine or foodstuff or mixing it with a base for formulation.  <P>COPYRIGHT: (C)2008,JPO&INPIT
NEW MATERIAL:A compound shown by the formula I (R1 is H, or OH; R2 is deuterium, or tritium). EXAMPLE:[1beta-<2>H]-1alpha-hydroxybitamin D3. USE:A reagent for testing pharmaceutical activity. PREPARATION:A 1-position labeled previtamin D3 derivative shown by the formula II is subjected to heat isomerization reaction in an inert organic solvent such as hexane, ether, methanol, etc. in an inert atmosphere such as preferably argon or nitrogen atmosphere containing no oxygen at 20-120 deg.C to give a compound shown by the formula I . The compound shown by the formula II is obtained by oxidizing a compound shown by the formula III with active manganese dioxide, followed by reduction with a reducing agent of deuterated or tritium reducing agent such as LiAl<2>H4, etc.
Carotid arteries are major blood vessels in the neck that supply blood and oxygen to the brain, but carotid stenosis occurs when carotid arteries are clogged by plaque. Revealing the cellular composition of the carotid artery at the single-cell level is essential for treating carotid atherosclerosis. However, there is no ready-to-use protocol for the preparation of single-cell suspensions from carotid arteries. To obtain a suitable protocol for the dissociation of normal carotid arteries at the single-cell level with less damage to cells, we designed a two-step digestion method by integrating the digestion process of collagenase/DNase and trypsin. Acridine orange/propidium iodide (AO/PI) dual-fluorescence counting was used to detect cell viability and concentration, and it was found that the single-cell suspension satisfied the requirements for single-cell sequencing, with the viability of cells over 85% and a high cell concentration. After single-cell data processing, a median of ~2500 transcripts per cell were detected in each carotid artery cell. Notably, a variety of cell types of the normal carotid artery, including vascular smooth muscle cells (VSMCs), fibroblasts, endothelial cells (ECs), and macrophages and dendritic cells (Mφ/DCs), were concurrently detectable. This protocol may be applied to prepare a single-cell suspension of blood vessels from other tissues with appropriate modifications.
Patient treated with bonded RME (Rapid Maxillary Expander) with a 13-mm screw. The acrylic splints of the bonded expander extended from the first deciduous molars through the first permanent molars.
Cerebral small vessel disease (SVD) is a leading cause of stroke and a major contributor to cognitive decline and dementia in the population. Evidences indicate that blood brain barrier dysfunction may play a significant role in VD pathogenesis. Recently, an inverse association of TRIM47 expression in brain and vascular tissues with extensive-SVD severity was reported in a human genome wide association study combined with summary-based Mendelian randomization studies and profiling of human loss-of-function allele carriers. Now, the inventors demonstrate TRIM47 is a key regulator of actin cytoskeleton organization through KEAP1/NRF2 signalling pathway and might be protective from oxidative stress in brain EC. In particular, the in vitro TRIM47 knockdown decreases directed EC migration and delays EC adhesion process with loss of actin cortical reorganization and focal adhesion contacts. Furthermore, RNA sequencing and BioID results indicate that TRIM47 knockdown in brain EC, represses the expression of genes associated with cytoskeleton and NRF2 antioxidant pathway through a potential interaction with KEAP1. Accordingly, the present invention relates to the use of Nrf2 activators for the treatment of SVD.
BACKGROUND: The optimal treatment for esophageal squamous cell carcinoma (ESCC) patients with postoperative recurrence remains controversial. We aimed to evaluate the effects of radiotherapy (RT) and chemoradiotherapy (CRT) on postoperative recurrence in ESCC patients.
METHODS: Recurrence ESCC patients who received salvage RT and CRT from January 2015 to January 2019 were retrospectively reviewed. Post-recurrence survival (PRS) and prognostic factors were evaluated by Kaplan-Meier and Cox proportional hazards models, respectively. Subgroup analyses were performed based on pathological lymph node (LN) status (negative/positive) to evaluate the differences in salvage treatments and toxic reaction.
RESULTS: A total of 170 patients were enrolled, with a median age of 60 years (range 43-77). No significant difference was found in the median PRS between the salvage RT and CRT groups (p > 0.05). Multivariate analysis revealed that TNM stage III and IV, macroscopic medullary type, and distant metastasis recurrence pattern were independent prognostic factors (all p < 0.05) for PRS. Salvage treatment was not associated with PRS (p = 0.897). However, in patients with negative LN, CRT was associated with prolonged survival (p = 0.043) and had no significant differences in toxic reactions compared to RT (p = 0.924). In addition, RT showed better prognoses (p = 0.020) and lower toxic reactions (p = 0.030) than CRT in patients with positive LNs.
CONCLUSIONS: Based on prognosis and toxic reactions, ESCC recurrence patients with negative LNs could benefit from CRT, but RT should be recommended for patients with positive LNs.
ETHNOPHARMACOLOGICAL RELEVANCE: Alzheimer's disease (AD) is the most prevalent neurodegenerative disease among old adults. As a traditional Chinese medicine, the herbal decoction Tian-Si-Yin consists of Morinda officinalis How. and Cuscuta chinensis Lam., which has been widely used to nourish kidney. Interestingly, Tian-Si-Yin has also been used to treat dementia, depression and other neurological conditions. However, its therapeutic potential for neurodegenerative diseases such as AD and the underlying mechanisms remain unclear.
AIM OF THE STUDY: To evaluate the therapeutic effect of the herbal formula Tian-Si-Yin against AD and to explore the underlying mechanisms.
MATERIALS AND METHODS: The N2a cells treated with amyloid β (Aβ) peptide or overexpressing amyloid precursor protein (APP) were used to establish cellular models of AD. The in vivo anti-AD effects were evaluated by using Caenorhabditis elegans and 3 × Tg-AD mouse models. Tian-Si-Yin was orally administered to the mice for 8 weeks at a dose of 10, 15 or 20 mg/kg/day, respectively. Its protective role on memory deficits of mice was examined using the Morris water maze and fear conditioning tests. Network pharmacology, proteomic analysis and ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry (UHPLC-MS/MS) were used to explore the underlying molecular mechanisms, which were further investigated by Western blotting and immunohistochemistry.
RESULTS: Tian-Si-Yin was shown to improve cell viability of Aβ-treated N2a cells and APP-expressing N2a-APP cells. Tian-Si-Yin was also found to reduce ROS level and extend lifespan of transgenic AD-like C. elegans model. Oral administration of Tian-Si-Yin at medium dose was able to effectively rescue memory impairment in 3 × Tg mice. Tian-Si-Yin was further shown to suppress neuroinflammation by inhibition of glia cell activation and downregulation of inflammatory cytokines, diminishing tau phosphoralytion and Aβ deposition in the mice. Using UHPLC-MS/MS and network pharmacology technologies, 17 phytochemicals from 68 components of Tian-Si-Yin were identified as potential anti-AD components. MAPK1, BRAF, TTR and Fyn were identified as anti-AD targets of Tian-Si-Yin from network pharmacology and mass spectrum.
CONCLUSIONS: This study has established the protective effect of Tian-Si-Yin against AD and demonstrates that Tian-Si-Yin is capable of improving Aβ level, tau pathology and synaptic disorder by regulating inflammatory response.
The present invention belongs to a compound iron-copper nutrition intensifying agent and a preparation method thereof. The chemical formula of the iron-copper nutrition intensifying agent is CuxFe1-xL2, wherein 0<x<0.3, and L<->=<->OOC-CH2-CH(NH3<+>)-COO<->. The raw materials comprise chemically pure copper carbonate, ferrous carbonate and biochemical reagents of aspartic acid. Right amount of water is added to the copper carbonate, and the copper carbonate and the water are stirred to obtain suspension I. In the same way, water is added to the ferrous carbonate to obtain suspension II. The suspension I and the suspension II are mixed, stirred by electromagnetism and heated to 40 to 50 DEG C., and the weighed aspartic acid is dissolved in the water to prepare aqueous solution of the aspartic acid. Then, the aqueous solution of the aspartic acid is dripped to the mixed suspension of the copper carbonate and the ferrous carbonate. The aspartic acid reacts with the copper carbonate and the ferrous carbonate, and the reaction time is 1.2 to 1.8 hours; after the reaction is completed, the mixed suspension is heated for concentrating, excessive water is evaporated, a target product is prepared by settling, aging, filtering and drying, and the product yield reaches 91.7 to 93.2%.
A scheme for securely transferring a patient data file to an intended recipient regardless of a transfer mode selected by a sender. Encryption system executing at the sender device is operative to encrypt each plaintext data line of a file, one by one, using a symmetric key and a starting IV that is incremented per each line, resulting in corresponding ciphertext lines added to an encrypted file. A hash is generated based on the encrypted file. An encrypted header containing the symmetric key, starting IV and the hash is generated using a public key of the recipient, which is appended to the encrypted file. The encrypted header and associated encrypted file are transmitted to the recipient in any manner. Upon receipt, the recipient decrypts the encrypted header using a private key to obtain the symmetric key, starting IV and the hash, which are used by the recipient to validate and decrypt the encrypted file on a line-by-line basis.